Month: January 2024

 PRESS RELEASE – REGULATED INFORMATION Article 14 of the Law of 2 May 2007 on disclosure of major holdings Mont-Saint-Guibert, Belgium, January 15, 2024, 7am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, today announces that it has received transparency notifications from François Rieger that can be consulted on the website of BioSenic, under the heading “Major shareholders & transparency notices”. The transparency notification indicates that the shareholdings held by François Rieger have crossed below the threshold of 15% as a result of a share lending on 10 January 2024.  The notification received from François Rieger dated 12 January 2024 contains the following information:Reason for the notification:Passive crossing...

PRESS RELEASE – INSIDE INFORMATION BioSenic reaches agreement on a binding term sheet with Phebra PTY Ltd. with respect to the development of the first oral formulation of arsenic troxide for cGvHD treatment A new binding term sheet has been signed to adapt the terms of two previous agreements under which Phebra granted Medsenic SAS, a subsidiary of BioSenic SA, an exclusive worldwide license agreement with a first marketing and distribution agreement (MDA) for OATO (oral arsenic trioxide) in the field of several targeted autoimmune diseases. Mont-Saint-Guibert, Belgium, January 15, 2024, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell therapy, and its subsidiary Medsenic SAS, today announce the signature of a binding term sheet...

– Top Schneider Electric executives attending World Economic Forum annual gathering. – Sustainability and energy resilience at the top of the corporate and public policy agenda. Far greater deployment of existing technologies is needed to keep climate change from spiraling out of control, Schneider Electric, the leader in the digital transformation of energy management and automation, urged today. Accelerating climate change, geopolitical tensions, see-sawing energy prices, and pressure from stakeholders to address these risks, have pushed environmental sustainability and energy resilience to the top of the corporate and policy agenda in recent years. They form the backdrop to the World Economic Forum’s annual meeting in Davos, Switzerland, from 15-19 January, which several senior Schneider Electric executives are attending. “With...

Novel class of antibiotics Bactericidal activity demonstrated in vitro and in vivo against broad range of Gram-negative bacteria, including multidrug-resistant strainsAllschwil, Switzerland, January 15, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has entered into an asset purchase agreement with Spexis AG (SIX: SPEX) for a preclinical program of antibiotics from a novel class, targeting Gram-negative bacteria, including multidrug-resistant strains.1 Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: “The acquired antibiotics are of a novel class, targeting the lipopolysaccharide transport in Gram-negative bacteria, which have been highlighted by the...

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces a new report examining musculoskeletal injury care and reimbursement in Australia that urges health payers and providers to resolve system-wide challenges hindering positive patient pathways from primary settings through to recovery. The Economist Impact – Musculoskeletal Injuries in Australia Report outlines the growing number of meniscal injury (MI) and rotator cuff (RC) injuries in Australia. It seeks to find solutions to ensure patients in Australia access better care for acute soft tissue injuries, and that a multi-party solution is adopted to address risks and gaps in current practices care looking at diagnostic techniques, referral mechanisms, and cost considerations of different reimbursement and/or compensation schemes.Smith+Nephew...

Preliminary results of the mandatory offer to acquire all shares in BW Energy Limited Reference is made to the mandatory offer by BW Group Limited (the “Offeror”) to acquire all outstanding shares (“Shares”) in BW Energy Limited (“BW Energy” or the “Company”) not already owned by the Offeror at an offer price of NOK 27.00 per share pursuant to the offer document (the “Offer Document”) dated 13 December 2023 (the “Offer”).  This action was taken in accordance with the Norwegian Securities Trading Act which obliges a shareholder becoming owner of shares representing 40% or more of the votes in the company to make an offer to purchase the remaining shares in the company. The offer period in the Offer (the “Offer Period”) expired at 16:30 (CET) on 12 January...

DISCLOSURE OF SHAREHOLDING Reference is made to the mandatory offer by BW Group Limited (the “Offeror” or “BW Group”) to acquire all outstanding shares (“Shares”) in BW Energy Limited (“BW Energy” or the “Company”) not already owned by the Offeror at an offer price of NOK 27.00 per share pursuant to the offer document (the “Offer Document”) dated 13 December 2023 (the “Offer”), and the announcement of the preliminary results of the Offer published earlier today, 14 January 2024. During 12 January 2024, being the last day of the offer period in the Offer, BW Group received acceptances for 30,493,614 Shares. In total, BW Group received acceptances of the Offer for 30,861,366 Shares. Following this BW Group holds 134,063,836 Shares in BW Energy, representing...

Singh’s appointment comes in support of the Company’s next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) — Bright Green Corporation (NASDAQ: BGXX) (“Bright Green” or “the Company”), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently developed health-related concerns. McAuley will assume an advisory role to Mr. Singh during the transition to continue facilitating the company’s...

New subgroup analysis from STRATUM study shows that individuals with an inadequate response, contraindication, or intolerance to steroids were 3.5 times more likely to achieve IGA Success with ZORYVE foam than an identical vehicle ZORYVE foam provided rapid and significant improvement in quality of life scores in patients 17 years and older Data presented at the 2024 Winter Clinical Dermatology Conference – HawaiiWESTLAKE VILLAGE, Calif., Jan. 14, 2024 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced a new subgroup analysis highlighting that adults and adolescents with seborrheic dermatitis who are contraindicated, intolerant, or unresponsive to topical steroids were 3.5 times...